ANGPTL3 Inhibition in Homozygous Familial Hypercholesterolemia
Open accessThe DOI matches its Crossref record; 4 of the 5 references it cites were found in a registry or an index.
Abstract
Evinacumab, a monoclonal antibody that blocks ANGPTL3, was administered to nine adults with homozygous familial hypercholesterolemia. At 4 weeks, LDL cholesterol was reduced by a mean of 49%, with a mean absolute change from baseline of −157 mg per deciliter.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Several novel therapies that potently reduce triglyceride levels are currently in development.[6][7][8]”
From Association of Triglyceride-Lowering LPL Variants and LDL-C–Lowering LDLR Variants With Risk of Coronary Heart Disease (2019) · cites this paper as [7]
In the citing paper
“It is of particular interest that, contrary to other lipid-lowering drugs, such as PCSK9 inhibitors,21,22 the lipid lowering effect of ANGPTL3 inhibition by evinacumab seems to be independent of the presence of residual LDLR activity, supporting the data obtained in animal models,6,10 as well as in a pilot clinical trial.9”
In the citing paper
“Interestingly, the LDL-C lowering effects of ANGPTL3 inhibition with either monoclonal antibodies or antisense oligonucleotides seems to be LDL receptor (LDLR) independent since marked LDL-C lowering is observed in both Ldlr knock-out (KO) mice6,8 and patients with homozygous familial hypercholesterolemia (hoFH).9”
In the citing paper
“Interestingly, the LDL-C lowering effects of ANGPTL3 inhibition with either monoclonal antibodies or antisense oligonucleotides seems to be LDL receptor (LDLR) independent since marked LDL-C lowering is observed in both Ldlr knock-out (KO) mice6,8 and patients with homozygous familial hypercholesterolemia (hoFH).9”
In the citing paper
“Based on the data collected during the parent clinical trials and other studies, LDL-C levels typically reach nadir after 4 weeks of receiving evinacumab infusion and remain generally stable at week 6.9”
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Cuchel, M., Bruckert, E., Ginsberg, H. N., Raal, F. J., Santos, R. D., Hegele, R. A., Kuivenhoven, J. A., Nordestgaard, B. G., Descamps, O. S., Steinhagen-Thiessen, E., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu274 · Cited by 1,057
Self-citationGenetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease
Dewey, F. E., Gusarova, V., Dunbar, R. L., O’Dushlaine, C., Schurmann, C., Gottesman, O., McCarthy, S., Van Hout, C. V., Bruse, S., Dansky, H. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612790 · Cited by 885
Self-citationExome Sequencing, ANGPTL3 Mutations, and Familial Combined Hypolipidemia
Musunuru, K., Pirruccello, J. P., Do, R., Peloso, G. M., Guiducci, C., Sougnez, C., Garimella, K. V., Fisher, S., Abreu, J., Barry, A. J., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002926 · Cited by 754
Rader, D. J., & Kastelein, J. J. P. (2014) · Circulation · doi:10.1161/circulationaha.113.001292 · Cited by 264
Cited by
Items 101–200 of 329
Apheresis for severe hypercholesterolaemia and elevated lipoprotein(a)
Waldmann, E., & Parhofer, K. G. (2019) · Pathology · doi:10.1016/j.pathol.2018.10.016 · Cited by 37
Moving Targets: Recent Advances in Lipid-Lowering Therapies
Larsen, L. E., Stoekenbroek, R. M., Kastelein, J. J. P., & Holleboom, A. G. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.312028 · Cited by 40
Current and Emerging Treatment Options for Hypertriglyceridemia: State-of-the-Art Review
Zimodro, J. M., Rizzo, M., & Gouni‐Berthold, I. (2025) · Pharmaceuticals · doi:10.3390/ph18020147 · Cited by 32
Stefanutti, C., Pang, J., Giacomo, S. D., Wu, X., Wang, X., Morozzi, C., Watts, G. F., & Lin, J. (2019) · Journal of clinical lipidology · doi:10.1016/j.jacl.2019.05.002 · Cited by 34
Yang, J. X., Song, Q., Niu, S., Chen, H., Petersen, R. B., Zhang, Y., & Huang, K. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30534 · Cited by 36
Pediatric Dyslipidemia—Beyond Familial Hypercholesterolemia
Lazarte, J., & Hegele, R. A. (2020) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2020.03.020 · Cited by 32
Treating Coronary Artery Disease: Beyond Statins, Ezetimibe, and PCSK9 Inhibition
Musunuru, K. (2020) · Annual Review of Medicine · doi:10.1146/annurev-med-080819-044918 · Cited by 34
New and emerging lipid-modifying drugs to lower LDL cholesterol
Kosmas, C. E., Pantou, D., Sourlas, A., Papakonstantinou, E. J., Uceta, R. E., & Guzman, E. (2021) · Drugs in Context · doi:10.7573/dic.2021-8-3 · Cited by 35
Yield of genetic association signals from genomes, exomes and imputation in the UK Biobank
Gaynor, S. M., Joseph, T., Bai, X., Zou, Y., Boutkov, B., Maxwell, E. K., Delaneau, O., Hofmeister, R. J., Krasheninina, O. A., Balasubramanian, S., et al. (2024) · Nature Genetics · doi:10.1038/s41588-024-01930-4 · Cited by 33
“hypercholesterolemia [4], and CRISPR editing of BCL11A for the treatment of sickle cell disease [5, 6].”
Circulating levels of PCSK9, ANGPTL3 and Lp(a) in stage III breast cancers
Chong, E. W., Joncas, F., Seidah, N. G., Calon, F., Diorio, C., & Gangloff, A. (2022) · BMC Cancer · doi:10.1186/s12885-022-10120-6 · Cited by 33
“This condition prompted the development of ANGPTL3 inhibitors to treat an almost opposite phenotype: homozygous familial hypercholesterolemia [41–43].”
BackgroundStefanutti, C., Chan, D. C., Giacomo, S. D., Morozzi, C., & Watts, G. F. (2022) · Pharmaceuticals · doi:10.3390/ph15111389 · Cited by 31
“It is noteworthy that evinacumab showed no significant effect on plasma Lp(a) concentration in clinical trials [17,18].”
BackgroundGu, J., Gupta, R. N., Cheng, H. K.-H., Xu, Y., & Raal, F. J. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae144 · Cited by 32
Inhibition of angiopoietin-like 3 for the management of severe hypercholesterolemia
Mohamed, F., Botha, T. C., & Raal, F. J. (2021) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000755 · Cited by 29
“Furthermore, in a post hoc analysis of 8 patients with 2% functional LDL-R activity, evinacumab showed a between group mean difference of 72.3% in LDL-C [22 && ].”
BackgroundInfluentialEmerging Anti-Atherosclerotic Therapies
Gluba-Brzózka, A., Franczyk, B., Rysz-Górzyńska, M., Ławiński, J., & Rysz, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212109 · Cited by 30
“The inhibition of ANGPTL3 is associated with triglyceride reduction (partly mediated by the hydrolysis of triglyceride-rich lipoproteins), causing a decrease in LDL and HDL cholesterol levels [58].”
BackgroundA VLP-based vaccine targeting ANGPTL3 lowers plasma triglycerides in mice
Fowler, A., Sampson, M. L., Remaley, A. T., & Chackerian, B. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.08.077 · Cited by 29
Haywood, J., Breese, K. J., Zhang, J., Waters, M. T., Bond, C. S., Stubbs, K. A., & Mylne, J. S. (2022) · Nature Communications · doi:10.1038/s41467-022-33185-0 · Cited by 27
Khoury, É., Brisson, D., Roy, N., Tremblay, G., & Gaudet, D. (2019) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2019.1602606 · Cited by 31
“Interestingly, the combination of evinacumab with lomitapide had a synergistic effect on several lipids parameters, reaching 90% LDL-C reduction in some HoFH patients [15,45].”
BackgroundSelf-citationFriend or foe for obesity: How hepatokines remodel adipose tissues and translational perspective
Zhang, Y., Wang, Y., & Liu, J. (2022) · Genes & Diseases · doi:10.1016/j.gendis.2021.12.011 · Cited by 33
New Therapeutic Approaches for Familial Hypercholesterolemia
Ajufo, E., & Rader, D. J. (2018) · Annual Review of Medicine · doi:10.1146/annurev-med-051215-030943 · Cited by 26
D’Erasmo, L., Bini, S., & Arca, M. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00967-8 · Cited by 28
“The treatment resulted in a mean 49% reduction of LDL-C from baseline [53].”
BackgroundIncreasing Lipolysis and Reducing Atherosclerosis
Tall, A. R. (2017) · New England Journal of Medicine · doi:10.1056/nejme1706907 · Cited by 26
Usefulness of Gemcabene in Homozygous Familial Hypercholesterolemia (from COBALT-1)
Gaudet, D., Durst, R. Y., Lepor, N. E., Bakker-Arkema, R. G., Bisgaier, C. L., Masson, L., Golden, L., Kastelein, J. J. P., Hegele, R. A., & Stein, E. A. (2019) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2019.09.010 · Cited by 27
Self-citationManaging dyslipidemia in patients with Type 2 diabetes
Tomlinson, B., Patil, N. G., Fok, M., & Lam, C. W. K. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1912734 · Cited by 33
Lipolytic enzymes and free fatty acids at the endothelial interface
Goldberg, I. J., Cabodevilla, A. G., Samovski, D., Cifarelli, V., Basu, D., & Abumrad, N. A. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.05.018 · Cited by 25
Ballantyne, C. M., & Norata, G. D. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf606 · Cited by 26
Pharmacogenomics Variability of Lipid-Lowering Therapies in Familial Hypercholesterolemia
Hindi, N. N., Alenbawi, J., & Nemer, G. M. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11090877 · Cited by 24
“optimize a minimal level of LDL-C in patients with homozygous and heterozygous FH independently of LDLR mutations [71,75].”
BackgroundLuo, F., Wu, P., Chen, J., Guo, Y., Wang, J., Li, X., & Fang, Z. (2018) · Lipids in Health and Disease · doi:10.1186/s12944-018-0835-0 · Cited by 23
Hypercholesterolemia and cardiovascular disease: Focus on high cardiovascular risk patients
Watts, G. F., Catapano, A. L., Masana, L., Zambon, A., Pirillo, A., & Tokgözoğlu, L. S. (2020) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2021.01.006 · Cited by 28
Metabolism of Triglyceride-Rich Lipoproteins
Borén, J., & Taskinen, M. (2021) · Handbook of experimental pharmacology · doi:10.1007/164_2021_520 · Cited by 30
Structure and Function of Angiopoietin-like Protein 3 (ANGPTL3) in Atherosclerosis
Lu, X. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666190621120523 · Cited by 22
Roundtable discussion: Familial chylomicronemia syndrome: Diagnosis and management
Brown, W. V., Goldberg, I., Duell, B., & Gaudet, D. (2018) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2018.02.018 · Cited by 21
Self-citationAngiopoietin-like 3: An important protein in regulating lipoprotein levels
Burks, K. H., Basu, D., Goldberg, I. J., & Stitziel, N. O. (2022) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2022.101688 · Cited by 23
Emerging drugs for the treatment of hypercholesterolemia
Bove, M., Cicero, A. F. G., & Borghi, C. (2019) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2019.1591372 · Cited by 21
“● Evinacumab (REGN1500): a mAb against Angiopoietin-like 3 (ANGPTL3) that increases the expression of Lipoprotein Lipase (LPL) causing a significant reduction of triglycerides and LDL-C; it is administered subcutaneously or intravenously with good preliminary results in terms of efficacy, tolerability, and safety [67,…”
BackgroundLomitapide for treatment of homozygous familial hypercholesterolemia: The Québec experience
Aljenedil, S., Alothman, L., Bélanger, A. M., Brown, L., Lahijanian, Z., Bergeron, J., Couture, P., Baass, A. W., Ruel, I. L., Brisson, D., et al. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.07.028 · Cited by 25
Self-citationTargeting PCSK9 and Beyond for the Management of Low-Density Lipoprotein Cholesterol
Mohamed, F., Mansfield, B. S., & Raal, F. J. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12155082 · Cited by 22
“The LDL-C reduction is not influenced by the specific genetic defect because the mechanism of action of evinacumab is independent of LDLR function [72,73].”
BackgroundMethodInfluentialMolecular aspects of hypercholesterolemia treatment: current perspectives and hopes
Ahangari, N., Ghayour‐Mobarhan, M., Sahebkar, A., & Pasdar, A. (2018) · Annals of Medicine · doi:10.1080/07853890.2018.1457795 · Cited by 24
“Importantly, recent data demonstrate that ANGPTL3 targeting seems to reduce LDL-C levels independently of the LDL receptor expression and thereby in a recent study where homozygous FH patients were receiving ANGPTL3 inhibitor (Evinacumab) a significant reduction of LDL-C was obtained on top of reductions already achie…”
BackgroundButler, A. A., Graham, J. L., Stanhope, K. L., Wong, S. C., King, S. M., Bremer, A. A., Krauss, R. M., Hamilton, J., & Havel, P. J. (2020) · Journal of Lipid Research · doi:10.1194/jlr.ra119000423 · Cited by 20
Triglyceride-Rich Lipoproteins
Kockx, M., & Kritharides, L. (2018) · Cardiology Clinics · doi:10.1016/j.ccl.2017.12.008 · Cited by 22
Newer and Emerging LDL-C Lowering Agents and Implications for ASCVD Residual Risk
Rikhi, R. R., & Shapiro, M. D. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11154611 · Cited by 19
“In a phase 2 trial involving nine participants with homozygous familial hypercholesterolemia with a mean LDL-C of 376 mg/dL, evinacumab was able to reduce LDL-C by 49% after 1 month [56].”
BackgroundRecent advances in the management and implementation of care for familial hypercholesterolaemia
Lan, N. S. R., Bajaj, A., Watts, G. F., & Cuchel, M. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106857 · Cited by 22
Self-citationChan, D. C., & Watts, G. F. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01254-y · Cited by 23
“%) in 9 patients with homozygous FH [59 ].”
Tada, H., Usui, S., Sakata, K., Takamura, M., & Kawashiri, M. (2020) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.60087 · Cited by 20
Novel Experimental Agents for the Treatment of Hypercholesterolemia
Pećin, I., & Reiner, Ž. (2021) · Journal of Experimental Pharmacology · doi:10.2147/jep.s267376 · Cited by 22
Triglyceride-Rich Lipoproteins and Novel Targets for Anti-atherosclerotic Therapy
Reiner, Ž. (2018) · Korean Circulation Journal · doi:10.4070/kcj.2018.0343 · Cited by 21
Surma, S., Romańczyk, M., & Filipiak, K. J. (2023) · Cardiology Journal · doi:10.5603/cj.a2021.0006 · Cited by 21
“[44] tested evinacumab in a group of 9 adults with familial hypercholesterolemia.”
BackgroundGenomic Innovation in Early Life Cardiovascular Disease Prevention and Treatment
Li, C., Pan, Y., Zhang, R., Huang, Z., Li, D., Han, Y., Larkin, C. T., Rao, V., Sun, X., & Kelly, T. N. (2023) · Circulation Research · doi:10.1161/circresaha.123.321999 · Cited by 22
Ruhanen, H., Haridas, P. A. N., Jauhiainen, M., & Olkkonen, V. M. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2020.158791 · Cited by 19
Jia, X., Liu, J., Mehta, A., Ballantyne, C. M., & Virani, S. S. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07082-x · Cited by 19
Transcriptomic Therapy for Dyslipidemias Utilizing Nucleic Acids Targeted at ANGPTL3
Watts, G. F., Raal, F. J., & Chan, D. C. (2021) · Future Cardiology · doi:10.2217/fca-2021-0096 · Cited by 18
Recent Updates in Hypertriglyceridemia Management for Cardiovascular Disease Prevention
Quispe, R., Sweeney, T. E., Varma, B., Agarwala, A., & Michos, E. D. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01052-4 · Cited by 18
Postprandial hyperlipidemia as a risk factor in patients with type 2 diabetes
Tomlinson, B., Chan, P., & Lam, C. W. K. (2020) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2020.1750949 · Cited by 22
“It was shown to be effective in homozygous familial hypercholesterolemia and reduced triglycerides in hypertriglyceridemic subjects [118,119].”
BackgroundWu, Y., Jiang, L., Zhang, H., Cheng, S., Wen, W., Xu, L., Zhang, F., Yang, Y., Wang, L., & Chen, J. (2021) · Genomics · doi:10.1016/j.ygeno.2021.05.036 · Cited by 20
Homozygous familial hypercholesterolemia: what treatments are on the horizon?
Bajaj, A., & Cuchel, M. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000677 · Cited by 19
“In a proof-ofprinciple study, a monoclonal antibody targeted to inhibit ANGPTL3, evinacumab, has been shown to decrease LDL-C levels by a mean 49% in nine individuals with HoFH when added to background lipidlowering therapy [26].”
BackgroundSelf-citationLDL-Cholesterol-Lowering Therapy
Pirillo, A., Norata, G. D., & Catapano, A. L. (2020) · Handbook of experimental pharmacology · doi:10.1007/164_2020_361 · Cited by 18
Reeskamp, L. F., Tromp, T. R., Huijgen, R., Stroes, E. S. G., Hovingh, G. K., & Grefhorst, A. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.11.013 · Cited by 21
Self-citationVekić, J., Zeljković, A., Stefanović, A., Bogavac‐Stanojević, N., Ilias, Ι., Silva‐Nunes, J., Stoian, A. P., Janež, A., & Rizzo, M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14040825 · Cited by 17
“A proof-of-concept study showed that the addition of evinacumab to standard lipid-lowering therapy of familial hypercholesterolemia further reduced LDL-C levels [58].”
BackgroundEvinacumab for treatment of familial hypercholesterolemia
Warden, B. A., & Duell, P. B. (2021) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2021.1955349 · Cited by 16
“Phase II study in patients with HoFH [56] 9 250 mg SQ on day 0 and 15 mg/ kg IV at week 2 LDL-C: 376 mg/dL ApoB: 226 mg/dL HDL-C: 39 mg/dL Non-HDL-C: 392 mg/dL TC: 431 mg/dL TG: 80 mg/dL Lp(a): 155 nmol/L Statin: 78% High intensity statin: 56% Ezetimibe: 78% PCSK9i: 33% Lomitapide: 22% Apheresis: 33% Triple therapy†:…”
BackgroundStefanutti, C., Chan, D. C., Zeppa, G., & Watts, G. F. (2024) · Journal of clinical lipidology · doi:10.1016/j.jacl.2024.05.006 · Cited by 17
The triglyceride to HDL-cholesterol ratio and chronic graft failure in renal transplantation
Anderson, J. L. C., Bakker, S. J. L., & Tietge, U. J. F. (2021) · Journal of clinical lipidology · doi:10.1016/j.jacl.2021.01.009 · Cited by 19
Targeting angiopoietin‐like 3 in atherosclerosis: From bench to bedside
Ling, P., Zheng, X., Luo, S., Ge, J., Xu, S., & Weng, J. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14450 · Cited by 16
“Recently, several studies have reported that evinacumab can effectively and favourably, from the perspective of antiatherogenic potential, modulate the lipid profile in HoFH patients.(3,11,93) Phase I studies showed that evinacumab was well tolerated and reduced fasting TG levels by 76%, LDL-C levels by 23% and HDL-C…”
BackgroundKhoury, É., Lauzière, A., Raal, F. J., Mancini, J., & Gaudet, D. (2022) · European Heart Journal - Case Reports · doi:10.1093/ehjcr/ytad029 · Cited by 15
Self-citationJi, B., Liu, J., Yin, Y., Xu, H. M., Shen, Q., & Yu, J. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-06124-0 · Cited by 15
Vahdat‐Lasemi, F., Farhoudi, L., Hosseinikhah, S. M., Santos, R. D., & Sahebkar, A. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.119235 · Cited by 14
Evinacumab: a new option in the treatment of homozygous familial hypercholesterolemia
Pirillo, A., & Catapano, A. L. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2090242 · Cited by 15
Florentin, M., Kostapanos, M. S., Anagnostis, P. G., & Liamis, G. L. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1691523 · Cited by 15
“inhibitors or a portacaval shunt) [67].”
Pedro‐Botet, J., Ascaso, J. F., Blasco, M., Brea, Á., Rodríguez, Á. D., Hernández‐Mijares, A., Pintó, X., & Millán, J. (2020) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2019.12.003 · Cited by 19
Melita, H., Manolis, A. A., Manolis, T. A., & Manolis, A. S. (2022) · PubMed · doi:10.1097/fjc.0000000000001160 · Cited by 19
Novel Therapeutics for Familial Chylomicronemia Syndrome
Izar, M. C. D. O., & Fonseca, F. A. H. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01295-x · Cited by 14
“Evinacumab has been administered intravenously at a dose of 15 mg/kg every four weeks in clinical studies [52, 53].”
Rodríguez‐Calvo, R., & Masana, L. (2019) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2018-105713 · Cited by 13
Novel therapies for familial hypercholesterolemia
Mohamed, F., Seedat, F., & Raal, F. J. (2020) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000590 · Cited by 16
Averna, M. R., & Catapano, A. L. (2021) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2021.10.017 · Cited by 14
Mechanisms of unusual response to lipid-lowering therapy: PCSK9 inhibition
Ouyang, M., Li, C., Hu, D., Peng, D., & Yu, B. (2022) · Clinica Chimica Acta · doi:10.1016/j.cca.2022.11.018 · Cited by 13
Tackling cardiometabolic risk in the Asia Pacific region
Li, J., Yeo, K. K., Tan, K., Ako, J., Krittayaphong, R., Tan, R., Aylward, P. E., Lam, C. S. P., Baek, S. H., Dalal, J. J., et al. (2020) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2020.100096 · Cited by 14
“Additional approaches involve directly targeting factors that influence metabolism of triglyceride rich lipoproteins [68, 69].”
Backgroundvan Gemert, Y., Kozijn, A. E., Pouwer, M. G., Kruisbergen, N. N. L., van den Bosch, M. H. J., Blom, A. B., Pieterman, E. J., Weinans, H., Stoop, R., Princen, H. M. G., et al. (2021) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2021.02.570 · Cited by 15
Liver cancer cells as the model for developing liver-targeted RNAi therapeutics
Hou, B., Qin, L., & Huang, L. (2023) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2023.01.007 · Cited by 14
Jia, X., Rifai, M. A., Liu, J., Agarwala, A., Gulati, M., & Virani, S. S. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00856-6 · Cited by 12
The Future of Lipid-Lowering Therapy
Zwol, W. H.-V., Rimbert, A., & Kuivenhoven, J. A. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8071085 · Cited by 14
“Phase I and II trials with either monoclonal antibodies (Evinacumab) or ASOs (IONIS-ANGPTL3-LRX) are in early development [17,82,83].”
BackgroundMethodLipids in Children and Links to Adult Vascular Disease.
Coakley, J. C. (2018) · Europe PMC (PubMed Central) · Cited by 16
Familial Hypercholesterolemia and Atherosclerosis: Animal Models and Therapeutic Advances
Xu, S., & Weng, J. (2020) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2020.02.007 · Cited by 13
Wilkinson, M. J., Bijlani, P., Davidson, M., Duell, P. B., Horan, M., Malloy, M. J., Newfield, R. S., Pradeep, P., Shah, P. K., Stock, E. O., et al. (2025) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.124.322364 · Cited by 13
Self-citationZhao, Y., Goto, M., Vaziri, N. D., Khazaeli, M., Liu, H., Farahanchi, N., Khanifar, E., Farzaneh, T., Haslett, P. A. J., Moradi, H., et al. (2020) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.120.000257 · Cited by 14
Bicciato, G., Arnold, M., Gebhardt, A., & Mira, K. (2021) · Current Opinion in Neurology · doi:10.1097/wco.0000000000001011 · Cited by 11
“antibody Evinacumab can reduce Lp(a) activity [49].”
Humphries, S. E., Ramaswami, U., & Hopper, N. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01177-0 · Cited by 11
Tailoring Treatment in Cardiovascular Diseases: The Role of Targeted Therapies
Dankar, R., Wehbi, J., & Refaat, M. M. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16040461 · Cited by 11
“Similarly, human phase I and II clinical trials showed consistent favorable results [13,37].”
BackgroundJiang, L., Stoekenbroek, R. M., Zhang, F., Wang, Q., Yu, W., Yuan, H., Cai, G., Chen, Y., Li, G., Yang, Y., et al. (2022) · Journal of clinical lipidology · doi:10.1016/j.jacl.2022.03.003 · Cited by 14
Hermel, M., Lieberman, M., Slipczuk, L. N., Rana, J. S., & Virani, S. S. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020459 · Cited by 12
“There was a 49 ± 23% (range, 25 to 90%) mean reduction in LDL-C from baseline to four weeks of follow-up, with an absolute decrease from baseline of 157 ± 90 mg/dL (range, 71 to 323 mg/dL) [67].”
BackgroundKraaijenhof, J. M., Tromp, T. R., Nurmohamed, N. S., Reeskamp, L. F., Langenkamp, M., Levels, J. H. M., Boekholdt, S. M., Wareham, N. J., Hoekstra, M., Stroes, E. S. G., et al. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.123.030476 · Cited by 14
Self-citationEDEM3 Modulates Plasma Triglyceride Level Through Its Regulation of LRP1 Expression
Xu, Y., Peloso, G. M., Nagai, T. H., Mizoguchi, T., Deik, A., Bullock, K. H., Lin, H., Musunuru, K., Yang, Q., Vasan, R. S., et al. (2019) · iScience · doi:10.1016/j.isci.2020.100973 · Cited by 11
“Inhibition of ApoC3 and ANGPTL3 showed strong effects in lowering the blood TG (Gaudet et al., 2014; Gaudet et al., 2017; Xu et al., 2018).”
BackgroundFH through the retrospectoscope
Thompson, G. R. (2020) · Journal of Lipid Research · doi:10.1194/jlr.tr120001001 · Cited by 11
“The latest potential advance in therapy is the angiopoietin-like protein 3 (ANGPTL3) inhibitor, evinacumab, which has been shown to lower LDL cholesterol by 49% in homozygotes (51) by a mechanism that is independent of the LDL receptor.”
BackgroundANGPLT3 in cardio-metabolic disorders
Su, X. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06248-6 · Cited by 11
Evinacumab for the treatment of homozygous familial hypercholesterolemia
Gao, Y.-L., Zhang, B., & Yang, J. (2022) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2022.2047934 · Cited by 10
Wright, J., & Subramanian, S. (2024) · Medical Clinics of North America · doi:10.1016/j.mcna.2024.03.005 · Cited by 12
Established and Emerging Nucleic Acid Therapies for Familial Hypercholesterolemia
Damase, T. R., Sukhovershin, R. A., Godin, B., Nasir, K., & Cooke, J. P. (2024) · Circulation · doi:10.1161/circulationaha.123.067957 · Cited by 11
“52 A randomized phase I trial involving 17 patients with HeFH demonstrated that ARO-ANG3 administered subcutaneously at different doses (100 mg, 200 mg, and 300 mg) reduced plasma levels of ANGPTL3 (62%– 92%), LDL-C (23%–37%), and triglycerides (25%– 43”
ANGPTL3 as a target for treating lipid disorders in type 2 diabetes patients
Chen, J., Luo, Q., Yi, Y., Wang, J., Chen, P., Luo, F., & Fang, Z. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02352-1 · Cited by 12
“In phase II and III studies, a reduction in LDL cholesterol of almost 50% was observed in patients with homozygous familial hypercholesterolemia (HoFH) receiving evinacumab versus placebo [55, 56], in which almost 50% of patients achieved LDL cholesterol 100 mg/dL ( 2.6 mmol/L) [56].”
BackgroundInfluentialIbi, D., Blauw, L. L., Noordam, R., Dollé, M. E. T., Jukema, J. W., Rosendaal, F. R., Christodoulides, C., Neville, M. J., Koivula, R. W., Rensen, P. C. N., et al. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.04.015 · Cited by 10
“Several therapies that enhance LPL-mediated clearance of TRL-derived TG are in development for CVD prevention [10 – 14].”
Poststatin era in atherosclerosis management: lessons from epidemiologic and genetic studies
Yvan‐Charvet, L., & Cariou, B. (2018) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000505 · Cited by 10
Biotechnology Approaches for the Treatment of Dyslipidemia
Parolini, C. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07017-6 · Cited by 10
“Similar results were observed in patients with homozygous familial hypercholesterolemia [107], supporting the evidence that evinacumab-lipid-lowering capacity is not linked to the presence of a functionally active LDL-R [108].”
ResultCurrent causes of death in familial hypercholesterolemia
Marco-Benedí, V., Bea, A. M., Cenarro, A., Jarauta, E., Laclaustra, M., & Civeira, F. (2022) · Lipids in Health and Disease · doi:10.1186/s12944-022-01671-5 · Cited by 9
“First, the genetic bases of heFH have been studied in depth and the genetic study provides a certainty diagnosis that obviates the diagnostic bias based on CVD risk as one of the major criteria for heFH diagnosis (9); and, second current lipid-lowering drugs including statins, ezetimibe and PCSK9 inhibitors have subst…”
BackgroundEffects of Inclisiran, Alirocumab, Evolocumab, and Evinacumab on Lipids: A Network Meta-Analysis
Zhang, L., Li, B., Chen, W., Li, W., Yang, H., & Pan, D. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm25248 · Cited by 11
“In a phase II clinical trial [51], 9 patients experienced at least one AE, such as nasopharyngitis, flu-like symptoms, dizziness, rhinorrhea, nausea, limb pain, and weakness, yet none discontinued treatment due to these side effects.”
Evinacumab for Homozygous Familial Hypercholesterolemia: The Italian Cohort of the ELIPSE HoFH Study
Iannuzzo, G., Calcaterra, I. L., Gentile, M., Stanzione, C., Ruberto, F. D., Taranto, M. D. D., Fortunato, G., & Minno, M. N. D. D. (2025) · Advances in Therapy · doi:10.1007/s12325-025-03160-4 · Cited by 10
“A phase 2, open-label, proof-of-concept study in patients with HoFH showed a mean 49% reduction from baseline LDL cholesterol levels with evinacumab at week 4 [31].”
Metadata
- Authors
- Gaudet, D., Gipe, D. A., Pordy, R., Ahmad, Z., Cuchel, M., Shah, P. K., Chyu, K.-Y., Sasiela, W. J., Chan, K.-C., Brisson, D., Khoury, E., Banerjee, P., Gusarova, V., Gromada, J., Stahl, N., Yancopoulos, G. D., & Hovingh, G. K.
- Affiliations
- Université de Montréal (CA)
- Regeneron (United States) (US)
- The University of Texas Southwestern Medical Center (US)
- University of Pennsylvania (US)
- Cedars-Sinai Medical Center (US)
- University of Amsterdam (NL)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-07-20
- Volume
- 377
- Issue
- 3
- Pages
- 296-297
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2738009647
- Cited by
- 323
- References
- 5
- Citations by year
- 2026: 13 · 2025: 26 · 2024: 29 · 2023: 23 · 2022: 41 · 2021: 58 · 2020: 62 · 2019: 36 · 2018: 30 · 2017: 4
- FWCI
- 36.99
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- ANGPTL3, evinacumab, homozygous familial hypercholesterolemia, LDL cholesterol lowering, monoclonal antibodies, cholesterol absorption inhibition, lipid-lowering therapy
- MeSH terms
- Angiopoietin-like Proteins, Angiopoietin-Like Protein 3, Antibodies, Monoclonal, Genotype, Humans, Hyperlipoproteinemia Type II, Cholesterol, LDL, Receptors, LDL, Angiopoietins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.